2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, Medeiros L, Wang M, Cohen J, Churnetski M, Hill B, Sawalha Y, Hernandez-Ilizaliturri F, Kothari S, Vose J, Bast M, Fenske T, Gari S, Maddocks K, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan A, Wagner-Johnston N, Messmer M, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg D, Glenn M, Inwards D, Ristow K, Karmali R, Kaplan J, Caimi P, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual J, Lue J, Diefenbach C, Fisher R, Barta S. Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma. Blood Advances 2023, 7: 7393-7401. PMID: 37874912, PMCID: PMC10758713, DOI: 10.1182/bloodadvances.2023010757.Peer-Reviewed Original ResearchConceptsProgression-free survivalMantle cell lymphomaOverall survivalPleomorphic variantMedian progression-free survivalB-cell non-Hodgkin lymphomaOutcomes of patientsAutologous hematopoietic transplantationNon-Hodgkin lymphomaComplete responsePatient characteristicsPoor prognosisHematopoietic transplantationCell lymphomaSecondary objectiveMonthsPatientsLymphomaSurvivalHigher scoresPrimary objectivePrognosisTransplantationNeoplasmsHigh-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Zayac A, Landsburg D, Hughes M, Bock A, Nowakowski G, Ayers E, Girton M, Hu M, Beckman A, Li S, Medeiros L, Chang J, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari M, Kothari S, Kress A, Xu M, Torka P, Sundaram S, Smith S, Naresh K, Karimi Y, Epperla N, Bond D, Farooq U, Saad M, Evens A, Pandya K, Naik S, Kamdar M, Haverkos B, Karmali R, Oh T, Vose J, Nutsch H, Rubinstein P, Chaudhry A, Olszewski A. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Advances 2023, 7: 6381-6394. PMID: 37171397, PMCID: PMC10598493, DOI: 10.1182/bloodadvances.2023009731.Peer-Reviewed Original ResearchConceptsProgression-free survivalMulti-institutional retrospective studyHigh-grade B-cell lymphomaOverall survivalB-cell lymphomaComplete responseMYC rearrangementRetrospective studyBCL6 rearrangementsGerminal center B-cell immunophenotypeHigh serum lactate dehydrogenaseHigh-risk clinical factorsBetter progression-free survivalIntensive chemotherapy programsPoor performance statusStage IV diseaseFirst-line regimensMain prognostic factorsDose-intense chemotherapyHigh-grade morphologic featuresSerum lactate dehydrogenaseB-cell immunophenotypeDA-EPOCHR-CHOPMost patients
2020
Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaPola-BRR DLBCLRefractory diffuse large B-cell lymphomaLonger progression-free survivalRecent phase II trialDiffuse large B-cell lymphomaProgression-free survivalTransplant-ineligible patientsPhase II trialUS payer perspectiveCost-effectiveness ratioII trialOverall survivalTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessIncremental costPolatuzumabRituximabLymphomaDLBCLOutcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics
Torka P, Kothari SK, Sundaram S, Li S, Medeiros LJ, Ayers EC, Landsburg DJ, Bond DA, Maddocks KJ, Giri A, Hess B, Pham LQ, Advani R, Liu Y, Barta SK, Vose JM, Churnetski MC, Cohen JB, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski AJ, Lee S, Hill BT, Burns TF, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri FJ. Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. Blood Advances 2020, 4: 253-262. PMID: 31945157, PMCID: PMC6988401, DOI: 10.1182/bloodadvances.2019000875.Peer-Reviewed Original ResearchConceptsInvolved-field radiation therapyProgression-free survivalIntensive immunochemotherapyB-cell lymphomaOveral survivalDHL patientsR-CHOPCR rateEntire cohortAggressive large B-cell lymphomaLarge B-cell lymphomaHigh-risk cytogeneticsOutcomes of patientsLower CR rateMulticenter retrospective studyDouble-hit lymphomaOverall response ratePaucity of dataIFRT groupStandard therapyRetrospective studyRadiation therapyTreatment groupsBCL6 rearrangementsPatients
2019
Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
Kothari S, Hillengass J, McCarthy PL, Holstein SA. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter? Current Hematologic Malignancy Reports 2019, 14: 39-46. PMID: 30671912, DOI: 10.1007/s11899-019-0497-7.Peer-Reviewed Original ResearchConceptsMinimal residual diseaseProgression-free survivalOverall survivalResidual diseaseImproved progression-free survivalRecent clinical trial dataRecent phase III studyMRD-negativity ratesPhase III studyBone marrow samplesClinical trial dataClinical trial designMRD negativityMRD statusIII studyMRD assessmentTreatment armsMultiple myelomaClinical trialsNegativity ratePrognostic biomarkerTreatment decisionsMarrow samplesSurrogate endpointsTrial designSurvival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. Journal Of Clinical Oncology 2019, 37: 471-480. PMID: 30615550, PMCID: PMC7554677, DOI: 10.1200/jco.18.00690.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, Mantle-CellMaleMiddle AgedNorth AmericaProgression-Free SurvivalRetrospective StudiesRisk AssessmentRisk FactorsRituximabTime FactorsTransplantation, AutologousYoung AdultConceptsImproved progression-free survivalProgression-free survivalMantle cell lymphomaTransplantation-eligible patientsOverall survivalMultivariable regression analysisRituximab eraCell lymphomaLarge cohortMedian progression-free survivalPropensity score-weighted analysisAdults age 65 yearsImproved overall survivalAge 65 yearsB-cell lymphomaRegression analysisCyclin D1 expressionEligible patientsFit patientsImproved OSInduction chemotherapyYounger patientsSurvival outcomesUnadjusted analysesInclusion criteria
2018
Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers
Kothari S, Li S, Medeiros L, Ayers E, Landsburg D, Bond D, Maddocks K, Giri A, Hess B, Pham L, Advani R, Liu Y, Barta S, Vose J, Churnetski M, Cohen J, Burkart M, Karmali R, Zurko J, Mehta A, Olszewski A, Lee S, Hill B, Burns T, Lansigan F, Rabinovich E, Peace D, Groman A, Attwood K, Hernandez-Ilizaliturri F, Torka P. Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. Blood 2018, 132: 451. DOI: 10.1182/blood-2018-99-111530.Peer-Reviewed Original ResearchInvolved field radiation therapyAggressive large B-cell lymphomaProgression-free survivalLarge B-cell lymphomaOverall response rateB-cell lymphomaDiffuse large B-cell lymphomaExtra-nodal diseaseOverall survivalR-CHOPBristol-Myers SquibbIFRT groupSeattle GeneticsSpeakers bureauCNS prophylaxisDistant relapseCR rateEntire cohortBCL6 rearrangementsStage IMYC rearrangementSimilar progression-free survivalImproved progression-free survivalMulti-center retrospective studyAdvisory Committee